Patients diagnosed with iron deficiency anemia Ferrous Fumarate , Iron Deficiency Anemia, IDA, randomized controlled trials
Conditions
Interventions
Thrice-Daily Oral Ferrous Fumarate ,Once-daily Oral Ferrous Fumarate
Active Comparator Drug,Active Comparator Drug
Thrice-Daily ,Once-daily
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 20 years or older 2. Hemoglobin levels less than or equal to 12 g/dL and serum ferritin levels less than or equal to 30 ng/mL
Exclusion criteria
Exclusion criteria: 1. Patients presenting with bleeding conditions necessitating a blood transfusion 2. Patients who have undergone a blood transfusion within 3. months prior to the commencement of follow up in the research project 3. Patients who have taken multivitamins or iron supplements within 2 weeks preceding enrollment in the study 4. Patients with any of the following conditions cancer undergoing chemotherapy or radiation therapy kidney disease liver disease alpha thalassemia or beta thalassemia hemolytic anemia bone marrow disorders inflammatory bowel disease active inflammation or infection pregnancy or lactation 5. Patients who are unable to tolerate oral iron supplements or with impaired iron absorption including those with a history of stomach or duodenum surgery or those receiving intravenous iron therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| increasing of hemoglobin at week 4 At baseline, and at 4-weeks after treatment Complete blood count | — |
Secondary
| Measure | Time frame |
|---|---|
| Increase serum ferritin levels at weeks 4 At baseline, and at 4-weeks after treatment serum ferritin level test | — |
Countries
Thailand
Contacts
Public Contactsasinee huntrakool
Faculty of Medicine, Chiang Mai University
Outcome results
None listed